Denis Buivolov, CFA
Contributor since: 2019
Paramount: Remains A Hidden Gem
BioMarin's Solid Pipeline Bears The First Fruit
Merck And Seagen: For And Against The Deal
Incyte: Growth Drivers Are Coming
Netflix And Roku: For And Against The Deal
Paramount Global: A Good Stock In Turbulent Time
Netflix: Not The Time To Write Off The Company
Regeneron: It's Time To Take Profit
Biogen: Not Yet Time To Buy
Vertex: More Opportunities Ahead
Incyte: All Attention On Opzelura
Paramount: Don't Fear The Increased Content Spending
Seagen: Bad Forecast But Good Investment
BioMarin: Keep Waiting For The Growth
Roku: Despite The Supply Chain Issues, The Shares Look Attractive
Uber: Let's Take A Ride
Peloton: Some Thoughts On The Latest News
Netflix: It Is Time To Think About The Stock Purchase
Activision Stock: Time To Reap Profits From Microsoft Deal
Zynga: It Is Time To Gain The Profit
Incyte: The Right Time To Buy The Stock
Seagen: SEA-CD40 Is The Next Growth Driver
Vertex: Waiting For The Pipeline Success
Peloton: Buy When The Fear Is On The Street
ViacomCBS: Buy The Streaming, Get The Legacy Business As A Gift
Discovery: A Bet On Discovery+WarnerMedia's Deal
Zynga: A Mobile Video Game Market Bet
ViacomCBS Stock: The Good Price To Buy The Solid Business
Activision Blizzard: The Sell-Off Gives An Investment Opportunity
BioMarin: The New Obstacle To Growth
BioMarin: More Opportunities Ahead
MGM's Deal: So Expensive, But Amazon Can Afford It
The First Glance At AT&T And Discovery's Deal
Regeneron: The Solid Growth At A Reasonable Price
Seagen: The New Oncology Hope
Vertex: An Undervalued Business With A Promising Pipeline
BioMarin: One Step Back Before The Jump
AbbVie And Roche Continue The Battle For The Leadership In AML And CLL Markets
Novartis Is Losing The Leadership In ALL And CML
The Future Of HCV Market Duopoly